A Metabolomic approach to clarifying the effect of AST-120 on 5/6 nephrectomized rats by capillary electrophoresis with mass spectrometry (CE-MS)

Yasutoshi Akiyama, Yoichi Takeuchi, Koichi Kikuchi, Eikan Mishima, Yasuaki Yamamoto, Chitose Suzuki, Takafumi Toyohara, Takehiro Suzuki, Atsushi Hozawa, Sadayoshi Ito, Tomoyoshi Soga, Takaaki Abe

Research output: Contribution to journalArticle

18 Citations (Scopus)

Abstract

The oral adsorbent AST-120 is composed of spherical carbon particles and has an adsorption ability for certain small-molecular-weight compounds that accumulate in patients with chronic kidney disease (CKD). So far, very few compounds are known to be adsorbed by AST-120 in vivo. To examine the effect of AST-120 in vivo, we comprehensively evaluated the plasma concentrations of 146 compounds (61 anions and 85 cations) in CKD model rats, with or without four weeks of treatment with AST-120. By capillary electrophoresis with mass spectrometry, we identified 6 anions and 17 cations that were significantly decreased by AST-120 treatment. In contrast, we also identified 2 cations that were significantly increased by AST-120. Among them, 4 anions, apart from indoxyl sulfate and hippurate, and 19 cations were newly identified in this study. The plasma levels of N-acetyl-neuraminate, 4-pyridoxate, 4-oxopentanoate, glycine, γ-guanidinobutyrate, N-γ-ethylglutamine, allantoin, cytosine, 5-methylcytosine and imidazole-4-acetate were significantly increased in the CKD model compared with the sham-operated group, and were significantly decreased by AST-120 treatment. Therefore, these 10 compounds could be added as uremic compounds that indicate the effect of AST-120 treatment. This study provides useful information not only for identifying the indicators of AST-120, but also for clarifying changes in the metabolic profile by AST-120 treatment in the clinical setting.

Original languageEnglish
Pages (from-to)1309-1322
Number of pages14
JournalToxins
Volume4
Issue number11
DOIs
Publication statusPublished - 2012 Nov

Fingerprint

Capillary electrophoresis
Metabolomics
Capillary Electrophoresis
Mass spectrometry
Rats
Mass Spectrometry
Cations
Chronic Renal Insufficiency
Anions
Indican
Allantoin
AST 120
5-Methylcytosine
Plasmas
Therapeutics
Metabolome
Cytosine
Glycine
Adsorbents
Adsorption

Keywords

  • AST-120
  • CE-MS
  • Uremic toxin

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis

Cite this

A Metabolomic approach to clarifying the effect of AST-120 on 5/6 nephrectomized rats by capillary electrophoresis with mass spectrometry (CE-MS). / Akiyama, Yasutoshi; Takeuchi, Yoichi; Kikuchi, Koichi; Mishima, Eikan; Yamamoto, Yasuaki; Suzuki, Chitose; Toyohara, Takafumi; Suzuki, Takehiro; Hozawa, Atsushi; Ito, Sadayoshi; Soga, Tomoyoshi; Abe, Takaaki.

In: Toxins, Vol. 4, No. 11, 11.2012, p. 1309-1322.

Research output: Contribution to journalArticle

Akiyama, Y, Takeuchi, Y, Kikuchi, K, Mishima, E, Yamamoto, Y, Suzuki, C, Toyohara, T, Suzuki, T, Hozawa, A, Ito, S, Soga, T & Abe, T 2012, 'A Metabolomic approach to clarifying the effect of AST-120 on 5/6 nephrectomized rats by capillary electrophoresis with mass spectrometry (CE-MS)', Toxins, vol. 4, no. 11, pp. 1309-1322. https://doi.org/10.3390/toxins4111309
Akiyama, Yasutoshi ; Takeuchi, Yoichi ; Kikuchi, Koichi ; Mishima, Eikan ; Yamamoto, Yasuaki ; Suzuki, Chitose ; Toyohara, Takafumi ; Suzuki, Takehiro ; Hozawa, Atsushi ; Ito, Sadayoshi ; Soga, Tomoyoshi ; Abe, Takaaki. / A Metabolomic approach to clarifying the effect of AST-120 on 5/6 nephrectomized rats by capillary electrophoresis with mass spectrometry (CE-MS). In: Toxins. 2012 ; Vol. 4, No. 11. pp. 1309-1322.
@article{549d8177c78c4720836329eb665d3b0e,
title = "A Metabolomic approach to clarifying the effect of AST-120 on 5/6 nephrectomized rats by capillary electrophoresis with mass spectrometry (CE-MS)",
abstract = "The oral adsorbent AST-120 is composed of spherical carbon particles and has an adsorption ability for certain small-molecular-weight compounds that accumulate in patients with chronic kidney disease (CKD). So far, very few compounds are known to be adsorbed by AST-120 in vivo. To examine the effect of AST-120 in vivo, we comprehensively evaluated the plasma concentrations of 146 compounds (61 anions and 85 cations) in CKD model rats, with or without four weeks of treatment with AST-120. By capillary electrophoresis with mass spectrometry, we identified 6 anions and 17 cations that were significantly decreased by AST-120 treatment. In contrast, we also identified 2 cations that were significantly increased by AST-120. Among them, 4 anions, apart from indoxyl sulfate and hippurate, and 19 cations were newly identified in this study. The plasma levels of N-acetyl-neuraminate, 4-pyridoxate, 4-oxopentanoate, glycine, γ-guanidinobutyrate, N-γ-ethylglutamine, allantoin, cytosine, 5-methylcytosine and imidazole-4-acetate were significantly increased in the CKD model compared with the sham-operated group, and were significantly decreased by AST-120 treatment. Therefore, these 10 compounds could be added as uremic compounds that indicate the effect of AST-120 treatment. This study provides useful information not only for identifying the indicators of AST-120, but also for clarifying changes in the metabolic profile by AST-120 treatment in the clinical setting.",
keywords = "AST-120, CE-MS, Uremic toxin",
author = "Yasutoshi Akiyama and Yoichi Takeuchi and Koichi Kikuchi and Eikan Mishima and Yasuaki Yamamoto and Chitose Suzuki and Takafumi Toyohara and Takehiro Suzuki and Atsushi Hozawa and Sadayoshi Ito and Tomoyoshi Soga and Takaaki Abe",
year = "2012",
month = "11",
doi = "10.3390/toxins4111309",
language = "English",
volume = "4",
pages = "1309--1322",
journal = "Toxins",
issn = "2072-6651",
publisher = "Multidisciplinary Digital Publishing Institute (MDPI)",
number = "11",

}

TY - JOUR

T1 - A Metabolomic approach to clarifying the effect of AST-120 on 5/6 nephrectomized rats by capillary electrophoresis with mass spectrometry (CE-MS)

AU - Akiyama, Yasutoshi

AU - Takeuchi, Yoichi

AU - Kikuchi, Koichi

AU - Mishima, Eikan

AU - Yamamoto, Yasuaki

AU - Suzuki, Chitose

AU - Toyohara, Takafumi

AU - Suzuki, Takehiro

AU - Hozawa, Atsushi

AU - Ito, Sadayoshi

AU - Soga, Tomoyoshi

AU - Abe, Takaaki

PY - 2012/11

Y1 - 2012/11

N2 - The oral adsorbent AST-120 is composed of spherical carbon particles and has an adsorption ability for certain small-molecular-weight compounds that accumulate in patients with chronic kidney disease (CKD). So far, very few compounds are known to be adsorbed by AST-120 in vivo. To examine the effect of AST-120 in vivo, we comprehensively evaluated the plasma concentrations of 146 compounds (61 anions and 85 cations) in CKD model rats, with or without four weeks of treatment with AST-120. By capillary electrophoresis with mass spectrometry, we identified 6 anions and 17 cations that were significantly decreased by AST-120 treatment. In contrast, we also identified 2 cations that were significantly increased by AST-120. Among them, 4 anions, apart from indoxyl sulfate and hippurate, and 19 cations were newly identified in this study. The plasma levels of N-acetyl-neuraminate, 4-pyridoxate, 4-oxopentanoate, glycine, γ-guanidinobutyrate, N-γ-ethylglutamine, allantoin, cytosine, 5-methylcytosine and imidazole-4-acetate were significantly increased in the CKD model compared with the sham-operated group, and were significantly decreased by AST-120 treatment. Therefore, these 10 compounds could be added as uremic compounds that indicate the effect of AST-120 treatment. This study provides useful information not only for identifying the indicators of AST-120, but also for clarifying changes in the metabolic profile by AST-120 treatment in the clinical setting.

AB - The oral adsorbent AST-120 is composed of spherical carbon particles and has an adsorption ability for certain small-molecular-weight compounds that accumulate in patients with chronic kidney disease (CKD). So far, very few compounds are known to be adsorbed by AST-120 in vivo. To examine the effect of AST-120 in vivo, we comprehensively evaluated the plasma concentrations of 146 compounds (61 anions and 85 cations) in CKD model rats, with or without four weeks of treatment with AST-120. By capillary electrophoresis with mass spectrometry, we identified 6 anions and 17 cations that were significantly decreased by AST-120 treatment. In contrast, we also identified 2 cations that were significantly increased by AST-120. Among them, 4 anions, apart from indoxyl sulfate and hippurate, and 19 cations were newly identified in this study. The plasma levels of N-acetyl-neuraminate, 4-pyridoxate, 4-oxopentanoate, glycine, γ-guanidinobutyrate, N-γ-ethylglutamine, allantoin, cytosine, 5-methylcytosine and imidazole-4-acetate were significantly increased in the CKD model compared with the sham-operated group, and were significantly decreased by AST-120 treatment. Therefore, these 10 compounds could be added as uremic compounds that indicate the effect of AST-120 treatment. This study provides useful information not only for identifying the indicators of AST-120, but also for clarifying changes in the metabolic profile by AST-120 treatment in the clinical setting.

KW - AST-120

KW - CE-MS

KW - Uremic toxin

UR - http://www.scopus.com/inward/record.url?scp=84870563668&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84870563668&partnerID=8YFLogxK

U2 - 10.3390/toxins4111309

DO - 10.3390/toxins4111309

M3 - Article

VL - 4

SP - 1309

EP - 1322

JO - Toxins

JF - Toxins

SN - 2072-6651

IS - 11

ER -